| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/25/2002 | WO2002033079A2 Human g-protein coupled receptor and uses thereof |
| 04/25/2002 | WO2002033063A1 Isocitrate dehydrogenase, gene thereof, and use of the same in the treatment of obesity, hyperlipidemia, and fatty liver in lipid biosynthesis |
| 04/25/2002 | WO2002033050A2 Methods and compositions for promoting the maturation of monocytes |
| 04/25/2002 | WO2002033044A2 Methods of high-throughput screening for internalizing antibodies |
| 04/25/2002 | WO2002032960A2 Methods of selecting compounds for modulation of bladder function |
| 04/25/2002 | WO2002032958A2 Polynucleotide and polypeptide sequences of human dendritic cell immunoreceptors |
| 04/25/2002 | WO2002032955A1 Human gene critical to fertility |
| 04/25/2002 | WO2002032953A2 Pregnancy-associated plasma protein-a2 (papp-a2) |
| 04/25/2002 | WO2002032904A1 New cephalotaxanes, their method of preparation and their use in treatment of cancers, leukemias, parasites including thus resistant to usual chemotherapeutic agents and as reversal agents |
| 04/25/2002 | WO2002032900A2 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 04/25/2002 | WO2002032897A1 Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists |
| 04/25/2002 | WO2002032893A2 Piperidine compounds as anti-allergic |
| 04/25/2002 | WO2002032888A1 Substituted dipeptides as growth hormone secretagogues |
| 04/25/2002 | WO2002032874A2 Substituted heterocyclic compounds for treating multidrug resistance |
| 04/25/2002 | WO2002032862A2 Use of p38 inhibitors for the treatment of smoke inhalation |
| 04/25/2002 | WO2002032458A2 System and methods for optimized drug delivery and progression of diseased and normal cells |
| 04/25/2002 | WO2002032454A1 Adjuvant composition comprising an immunostimulatory oligonucleotide and a tocol |
| 04/25/2002 | WO2002032445A2 Inhibition of the interaction between oxidized proteins and cd36 or the active mechanism thereof |
| 04/25/2002 | WO2002032435A2 A composition including a platelet activating factor inhibitor and an antioxidant which interferes with the arachidonic acid cascade |
| 04/25/2002 | WO2002032430A1 Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases |
| 04/25/2002 | WO2002032429A2 Use of inhibitors of progesterone receptor for treating cancer |
| 04/25/2002 | WO2002032428A1 Oral formulation comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor |
| 04/25/2002 | WO2002032424A1 Stable compositions of oxapenem-3-carboxylic acids by co-lyophilisation with pharmaceutical carriers |
| 04/25/2002 | WO2002032422A2 Ep4 receptor inhibitors to treat rheumatoid arthritis |
| 04/25/2002 | WO2002032419A2 Methods for modulating bladder function |
| 04/25/2002 | WO2002032418A1 Therapeutic use of aerosolized s-nitrosoglutathione in cystic fibrosis |
| 04/25/2002 | WO2002032416A2 Inhibition of emetic effect of metformin with 5-ht3 receptor antagonists |
| 04/25/2002 | WO2002032414A2 Ribavirin-pegylated interferon alfa hcv combination therapy |
| 04/25/2002 | WO2002032412A2 Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders |
| 04/25/2002 | WO2002032411A2 Combination of statins and sorbitol dehydrogenase inhibitors |
| 04/25/2002 | WO2002032410A2 Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders |
| 04/25/2002 | WO2002032407A2 Use of hyaluronic acid derivatives for the prevention of inflammatory arthritis |
| 04/25/2002 | WO2002032400A1 Liposomal formulation of mitoxantrone |
| 04/25/2002 | WO2002032397A2 Electroprocessing in drug delivery and cell encapsulation |
| 04/25/2002 | WO2002032394A1 Delivery system and method of treating or preventing otitis media |
| 04/25/2002 | WO2002032393A2 Medicinal composition and in particular its use in fluid therapy |
| 04/25/2002 | WO2002032378A2 Fusion cells and cytokine compositions for treatment of disease |
| 04/25/2002 | WO2002032374A2 Methods for treating il-18 mediated disorders |
| 04/25/2002 | WO2002032234A1 Anti-stress composition designed to be mainly incorporated in nutritional carriers |
| 04/25/2002 | WO2002022112A9 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| 04/25/2002 | WO2002002128A3 Oral compositions comprising antimicrobial agents |
| 04/25/2002 | WO2001089496A3 Compositions and methods for treating otic, ophthalmic and nasal infections comprising quinolone antibiotics |
| 04/25/2002 | WO2001088136A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 04/25/2002 | WO2001078698A3 Use of ngf-antagonists for the prevention or treatment of chronic visceral pain |
| 04/25/2002 | WO2001076574A3 Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists |
| 04/25/2002 | WO2001066110A3 METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA2 INHIBITORS |
| 04/25/2002 | WO2001064205A3 Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor |
| 04/25/2002 | WO2001062300A3 Caspase activated prodrugs therapy |
| 04/25/2002 | WO2001060975A3 Gene disruption methodologies in fungi for drug target discovery |
| 04/25/2002 | WO2001060174A3 Weight loss induced by reduction in neuropeptide y level |
| 04/25/2002 | WO2001058450A3 Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation |
| 04/25/2002 | WO2001057240A3 Interaction of nmda receptor with protein tyrosine phosphatase |
| 04/25/2002 | WO2001056552A3 Farnesyl protein transferase inhibitors for treating breast cancer |
| 04/25/2002 | WO2001054652A3 A method of inducing autovaccination against HIV infection using structured treatment interruptions |
| 04/25/2002 | WO2001052904A3 Pharmaceutical compositions and methods of treatment based on VEGF antisense oligonucleotides |
| 04/25/2002 | WO2001047533A3 INHIBITION OF GSK-3$g(b) |
| 04/25/2002 | WO2001045740A3 Compositions and methods for treatment of breast cancer |
| 04/25/2002 | US20020049389 Noninvasive measurement of chemical substances |
| 04/25/2002 | US20020049249 PPAR receptor activator compounds for treating cutaneous disorders/afflictions |
| 04/25/2002 | US20020049247 Administering lyposomes of photosensitive receptors or ligands targeted to specific tissues, exposure to light causing destruction of bound tissues; treatment of eye neovascular disease due to macular degeneration, diabetes... |
| 04/25/2002 | US20020049244 Treatment of disease or disease symptoms mediated by eicosanoid 20-hydroxyeicosatetraenoic acid (20-HETE) a potent constrictor of renal, cerebral and skeletal muscle arterioles |
| 04/25/2002 | US20020049237 Statin-MMP inhibitor combinations |
| 04/25/2002 | US20020049233 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor |
| 04/25/2002 | US20020049232 Method of treating parkinson's disease |
| 04/25/2002 | US20020049211 Combination treatment for depression and anxiety |
| 04/25/2002 | US20020049200 Use of a methylol-containing compound to treat tumors |
| 04/25/2002 | US20020049198 Administering to a patient having or at risk of having osteoarthritis, a therapeutically effective amount of an bicyclicaromatic or heteroaromatic compound containing amine and hydroxy groups |
| 04/25/2002 | US20020049183 Phospholipids, espeically phosphatidylethanolamines, covalently bound to physiologically acceptable monomers or polymers. |
| 04/25/2002 | US20020049177 Detecting an aberrant level or bioactivity of or screening for a Wnt pathway component or a frizzled related protein gene product |
| 04/25/2002 | US20020049171 Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria |
| 04/25/2002 | US20020049170 Method for reducing toxicity of combined chemotherapies |
| 04/25/2002 | US20020049164 Prodrugs of DP IV-inhibitors |
| 04/25/2002 | US20020049158 Increasing bioavailability of a drug which is not readily absorbed in the digestive tract |
| 04/25/2002 | US20020049157 Use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock |
| 04/25/2002 | US20020049151 Therapeutic approaches to diseases by suppression of the NURR subfamily of nuclear transcription factors |
| 04/25/2002 | US20020048801 Peptide with enzymatic activity; for use as diagnostic tools in detecting cancer and cardiovascular and liver disorders |
| 04/25/2002 | US20020048794 Polypeptides for use in the diagnosis and treatment of skin disorders, cancer, vision and demyelination defects, inflammation, glomerculonephritis, Kaposi's sarcoma, angiogenesis, sarcoidosis, osteoarthritis and aneurysm |
| 04/25/2002 | US20020048786 Nucleotide sequences for use in the treatment of infections, arthritis, karposi's sarcoma, allergies, asthma, nervous system and autoimmune diseases |
| 04/25/2002 | US20020048785 Novel polypeptides within the tumor necrosis factor receptor superfamily and uses therefor |
| 04/25/2002 | US20020048769 Protein-protein interactions in neurodegenerative disorders |
| 04/25/2002 | US20020048764 Human PEM as a target for birth contol and treatment of Alzheimer's disease |
| 04/25/2002 | US20020048748 Controlling human lymphocyte leukemia/lymphoma viruses immunodeficiency virus; obtain human, administer viricide and interleukin, monitor human for adjust in viral activity |
| 04/25/2002 | US20020048599 Method for increasing tissue perfusion by co-administration of an agent that increases cGMP synthesis and an agent that inhibits cGMP degradation |
| 04/25/2002 | US20020048584 Patients that are treated with HAART are then treated with an intensification regimen wherein hydroxyurea and didanosine (ddI) are given; followed by addition of compounds, such as OKT3 and IL-2, that activate latently infected cells |
| 04/25/2002 | US20020048583 Combining ex vivo an antigen and an antigen-presenting cell binding agent specific for the antigen, and administering the composition to a patient suffering from a disease associated with the antigen |
| 04/25/2002 | US20020048565 Mammalian tolloid-like gene and protein |
| 04/25/2002 | US20020048271 Methods and composition for restoring conformational stability of a protein of the p53 family |
| 04/25/2002 | CA2818654A1 Pregnancy-associated plasma protein-a2 (papp-a2) |
| 04/25/2002 | CA2464121A1 Pregnancy-associated plasma protein-a2 (papp-a2) |
| 04/25/2002 | CA2464092A1 Electroprocessing in drug delivery and cell encapsulation |
| 04/25/2002 | CA2453140A1 Inhibition of the interaction between oxidized proteins and cd36 or the active mechanism thereof |
| 04/25/2002 | CA2426592A1 Combination of statins and sorbitol dehydrogenase inhibitors |
| 04/25/2002 | CA2426487A1 Ep4 receptor inhibitors to treat rheumatoid arthritis |
| 04/25/2002 | CA2426403A1 Isocitrate dehydrogenase, gene thereof, and use of the same in the treatment of obesity, hyperlipidemia, and fatty liver in lipid biosynthesis |
| 04/25/2002 | CA2426366A1 Fusion cells and cytokine compositions for treatment of disease |
| 04/25/2002 | CA2426120A1 Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders |
| 04/25/2002 | CA2426103A1 New cephalotaxanes, their method of preparation and their use in treatment of cancers, leukemias, parasites including thus resistant to usual chemotherapeutic agents and as reversal agents |
| 04/25/2002 | CA2426083A1 Use of hyaluronic acid derivatives for inhibiting inflammatory arthritis |
| 04/25/2002 | CA2425963A1 Human kinases |
| 04/25/2002 | CA2425831A1 Oral formulation comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor |